Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernd Meibohm

Showing results (141-150 of 171) with videos related to

Pageof 18
Sort By:
Frontiers in Tuberculosis|June 3, 2026
Dose optimization of inhaled tigecycline in humans to overcome inherent adverse events and maximize bacterial clearance using a physiologically-based pharmacokinetic modeling approachHyunseo Park, Amarinder Singh, Ashish Srivastava, et al.
Plos One|February 8, 2014
Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosisRakesh, David F Bruhn, Michael S Scherman, et al.
Antimicrobial Agents and Chemotherapy|September 30, 2025
Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosisNathan Peroutka-Bigus, Michael S Scherman, Firat Kaya, et al.
Elife|October 8, 2024
A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamidesMalik Zohaib Ali, Taru S Dutt, Amy MacNeill, et al.
Biorxiv : the Preprint Server for Biology|August 13, 2025
Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosisNathan Peroutka-Bigus, Michael S Sherman, Firat Kaya, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2023
A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled SpectinamidesMalik Zohaib Ali, Taru S Dutt, Amy MacNeill, et al.
Cancer Letters|June 7, 2024
Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancerDamilola Oluwalana, Kelli L Adeleye, Raisa I Krutilina, et al.
British Journal of Pharmacology|January 13, 2018
Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkeyAndreas M Hohlbaum, Hendrik Gille, Stefan Trentmann, et al.
Antimicrobial Agents and Chemotherapy|September 26, 2025
Characterization of new mouse models of acute and chronic <i>Mycobacterium abscessus</i> infection for antimicrobial drug screeningIlham M Alshiraihi, Ha Lam, Brennen T Troyer, et al.
Bioorganic & Medicinal Chemistry Letters|August 30, 2024
Enhancing the therapeutic window for Spectinamide anti-tuberculosis Agents: Synthesis, Evaluation, and activation of phosphate prodrug 3408Jiuyu Liu, Pradeep B Lukka, Victoria A Ektnitphong, et al.
Pageof 18

Showing results (141-150 of 171) with videos related to

Sort By:
Pageof 18
Frontiers in Tuberculosis|June 3, 2026
Dose optimization of inhaled tigecycline in humans to overcome inherent adverse events and maximize bacterial clearance using a physiologically-based pharmacokinetic modeling approachHyunseo Park, Amarinder Singh, Ashish Srivastava, et al.
Plos One|February 8, 2014
Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosisRakesh, David F Bruhn, Michael S Scherman, et al.
Antimicrobial Agents and Chemotherapy|September 30, 2025
Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosisNathan Peroutka-Bigus, Michael S Scherman, Firat Kaya, et al.
Elife|October 8, 2024
A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamidesMalik Zohaib Ali, Taru S Dutt, Amy MacNeill, et al.
Biorxiv : the Preprint Server for Biology|August 13, 2025
Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosisNathan Peroutka-Bigus, Michael S Sherman, Firat Kaya, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2023
A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled SpectinamidesMalik Zohaib Ali, Taru S Dutt, Amy MacNeill, et al.
Cancer Letters|June 7, 2024
Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancerDamilola Oluwalana, Kelli L Adeleye, Raisa I Krutilina, et al.
British Journal of Pharmacology|January 13, 2018
Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkeyAndreas M Hohlbaum, Hendrik Gille, Stefan Trentmann, et al.
Antimicrobial Agents and Chemotherapy|September 26, 2025
Characterization of new mouse models of acute and chronic <i>Mycobacterium abscessus</i> infection for antimicrobial drug screeningIlham M Alshiraihi, Ha Lam, Brennen T Troyer, et al.
Bioorganic & Medicinal Chemistry Letters|August 30, 2024
Enhancing the therapeutic window for Spectinamide anti-tuberculosis Agents: Synthesis, Evaluation, and activation of phosphate prodrug 3408Jiuyu Liu, Pradeep B Lukka, Victoria A Ektnitphong, et al.
Pageof 18